Target Overview

Drug Target: GLP-1 receptor

Indication area: Metabolic & Cardiometabolic Disorders

Therapeutic class: Incretin-based therapies

Specific Indications:  Type 2 Diabetes, Obesity

Summary: The GLP-1 receptor is a G protein-coupled receptor that, upon activation, manages blood glucose and appetite by modulating hormone levels and slowing digestion.

‍Disease Biology

Disease: Obesity

Prevalence: More than 1 billion

Disease Mechanism:

Obesity is a complex, chronic disease characterized by excessive fat accumulation that impairs health due to a biological dysfunction in the way the brain and gut communicate about energy storage . In many people with obesity, the brain’s "set point" for weight is recalibrated higher. The hormones that should signal fullness are often under-produced or ignored by the brain, while hunger signals remain overactive. This creates a cycle where the body fights to maintain a higher weight, leading to systemic inflammation and a significantly increased risk for heart disease and various cancers .

Why Target the drug target is used in this disease?

The GLP-1 receptor plays a central role in regulating appetite, satiety, and energy intake through the gut–brain axis. Activation of this receptor enhances post-meal satiety, slows gastric emptying, and reduces caloric intake by modulating hypothalamic appetite pathways. In obesity, impaired incretin signaling contributes to dysregulated hunger and overeating, making GLP-1 receptor modulation an effective strategy to restore physiological appetite control and support sustained weight loss.

‍

Disease: Type 2 Diabetes

Prevalence: 589 million adults

Disease Mechanism:

Type 2 Diabetes is a systemic failure of glucose regulation characterized by insulin resistance and declining insulin production. Normally, gut hormones signal the pancreas to prepare for sugar, but this "incretin effect" falters in diabetics. As muscle and liver cells ignore insulin, blood sugar remains elevated. The pancreas overcompensates until its beta cells exhaust and fail. This crisis is compounded by a "leaky" liver overproducing glucose and a pancreas releasing excess glucagon. Ultimately, this breakdown in communication between the gut, liver, and pancreas creates a chronic cycle of high blood sugar that progressively damages the body's organs.

Why Target the GLP-1 Receptor in Type 2 Diabetes
Activating the GLP-1 receptor is like "resetting" the body's glucose thermostat. It forces the pancreas to release insulin only when sugar is present, which prevents the dangerous blood sugar spikes and crashes seen with older medicines like sulfonylureas. It also tells the liver to stop producing unnecessary sugar by suppressing glucagon. Beyond just lowering sugar, these drugs protect the heart and kidneys, organs that are usually the first to suffer in diabetes. Because the mechanism is glucose-dependent, it has a very low risk of causing "hypoglycemia" (dangerously low blood sugar), which was a major limitation of older therapies.

While the GLP-1 receptor is a powerful tool for weight management, its role in treating Type 2 Diabetes (T2D) is perhaps its most long-standing clinical application. Affecting a staggering 589 million adults globally, T2D is more than just "high blood sugar"—it is a systemic failure of the body’s glucose regulation mechanisms.

Drugs in the Market

About Elucidata

Elucidata helps biopharma companies structure their messy biomedical data at scale. Our platform, Polly, a powerful harmonization engine is utilized by trained experts to curate diverse data types, annotate metadata, and ensure consistent processing at affordable costs. Polly's advanced technology accommodates 25+ R&D data types, catering to teams in pre-clinical drug discovery and diagnostics R&D.

‍